stocks logo

BMEA

Biomea Fusion Inc
$
1.650
-0.15(-8.333%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.810
Open
1.800
VWAP
--
Vol
890.07K
Mkt Cap
94.09M
Low
1.650
Amount
--
EV/EBITDA(TTM)
--
Total Shares
35.94M
EV
56.11M
EV/OCF(TTM)
--
P/S(TTM)
--
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Show More
6 Analyst Rating
up Image
536.36% Upside
Wall Street analysts forecast BMEA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMEA is 10.50 USD with a low forecast of 3.00 USD and a high forecast of 30.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
up Image
536.36% Upside
Current: 1.650
sliders
Low
3.00
Averages
10.50
High
30.00
Citi
Buy
downgrade
$22 -> $9
2025-07-16
Reason
Citi lowered the firm's price target on Biomea Fusion to $9 from $22 and keeps a Buy rating on the shares. The firm cites the company's strategic realignment for the target cut. With the focus now metabolic disease, Biomea is no longer pursuing oncology, the analyst tells investors in a research note.
H.C. Wainwright
Joseph Pantginis
Buy
downgrade
$18 -> $4
2025-06-23
Reason
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Biomea Fusion to $4 from $18 and keeps a Buy rating on the shares, citing the June fundraising with "significant dilution" for the firm's revised target. At the ADA meeting, Biomea presented additional preclinical data highlighting icovamenib's potential for combination therapies, notes the analyst, who contends that icovamenib "stands out" for combination approaches and lean mass preservation.
Piper Sandler
Edward Tenthoff
Overweight
initiated
$7
2025-06-02
Reason
Piper Sandler analyst Edward Tenthoff assumedcoverage of Biomea Fusion with an Overweight rating and $7 price target. The company is developing icovamenib to treat diabetes, a covalent menin inhibitor, the analyst tells investors in a research note. Piper views Biomea as an emerging diabetes and obesity play.
Barclays
Peter Lawson
Hold
Maintains
$11 → $3
2025-04-02
Reason
Barclays lowered the firm's price target on Biomea Fusion to $3 from $11 and keeps an Equal Weight rating on the shares following the Q4 report. The company's catalysts are on track with a focus around a path forward for icovamenib, the analyst tells investors in a research note.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$40
2025-04-01
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$40
2025-03-31
Reason

Valuation Metrics

The current forward P/E ratio for Biomea Fusion Inc (BMEA.O) is -1.19, compared to its 5-year average forward P/E of -3.93. For a more detailed relative valuation and DCF analysis to assess Biomea Fusion Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.93
Current PE
-1.19
Overvalued PE
-1.02
Undervalued PE
-6.84

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.49
Current EV/EBITDA
-0.73
Overvalued EV/EBITDA
2.09
Undervalued EV/EBITDA
-7.06

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
-27.64%
-29.71M
Operating Profit
FY2025Q1
YoY :
-25.09%
-29.26M
Net Income after Tax
FY2025Q1
YoY :
-26.61%
-0.80
EPS - Diluted
FY2025Q1
YoY :
-19.95%
-25.67M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
100.6K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
657.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

BMEA News & Events

Events Timeline

2025-07-24 (ET)
2025-07-24
07:12:01
Biomea Fusion appoints Julianne Averill to board of directors
select
2025-06-23 (ET)
2025-06-23
07:30:38
Biomea Fusion announces presentation of icovamenib preclinical, clinical data
select
2025-06-20 (ET)
2025-06-20
08:45:01
Largest borrow rate increases among liquid names
select
Sign Up For More Events

News

5.0
07-24Newsfilter
Biomea Fusion Appoints Julianne Averill to its Board of Directors
4.5
06-18Benzinga
Crude Oil Moves Higher; US Weekly Jobless Claims Decline
9.0
06-18Newsfilter
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
Sign Up For More News

FAQ

arrow icon

What is Biomea Fusion Inc (BMEA) stock price today?

The current price of BMEA is 1.65 USD — it has decreased -8.33 % in the last trading day.

arrow icon

What is Biomea Fusion Inc (BMEA)'s business?

arrow icon

What is the price predicton of BMEA Stock?

arrow icon

What is Biomea Fusion Inc (BMEA)'s revenue for the last quarter?

arrow icon

What is Biomea Fusion Inc (BMEA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Biomea Fusion Inc (BMEA)'s fundamentals?

arrow icon

How many employees does Biomea Fusion Inc (BMEA). have?

arrow icon

What is Biomea Fusion Inc (BMEA) market cap?